---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-031974"
form_type: "8-K/A"
ticker: "NMRA"
cik: "0001885522"
company_name: "Neumora Therapeutics, Inc."
filed_at: "2025-02-21T23:59:59+00:00"
generated_at: "2026-05-26T07:15:16.470022+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Neumora Therapeutics appoints Paul Berns as Chairman & CEO, Gosebruch exits

## Summary
- Henry Gosebruch separates as CEO; receives 12-month base salary, 2025 target bonus, 18-month COBRA, 2024 bonus, and 12-month option exercise period.
- Paul L. Berns appointed Chairman & CEO with $700,000 base salary and 60% annual bonus target, effective Feb 14, 2025.
- Berns receives option to purchase 2,000,000 shares vesting over 4 years (25% after 1 year, monthly thereafter).
- Berns severance: 12 months salary + bonus (non-CIC); 24 months salary + 2x bonus + equity acceleration (CIC-related).

## SEC filing metadata
- accession: 0001193125-25-031974
- form_type: 8-K/A
- ticker: NMRA
- cik: 0001885522
- company_name: Neumora Therapeutics, Inc.
- filed_at: 2025-02-21T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1885522/000119312525031974/0001193125-25-031974-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1885522/000119312525031974/d862857d8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-031974
- JSON: https://secwatch.observer/filing/0001193125-25-031974.json
- Plain text: https://secwatch.observer/filing/0001193125-25-031974.txt

## Key facts
- Executive change
  Henry Gosebruch departed as President and Chief Executive Officer at Neumora Therapeutics, Inc..
  - Action: separated
  - Role: President and Chief Executive Officer
  source text: the Company has entered into a Separation Agreement, dated February 14, 2025, with Henry Gosebruch, the Company’s former President and Chief Executive Officer
  evidence_url: https://www.sec.gov/Archives/edgar/data/1885522/000119312525031974/0001193125-25-031974-index.htm
- Executive change
  Paul L. Berns was appointed as Chairman and Chief Executive Officer at Neumora Therapeutics, Inc..
  - Action: appointed
  - Role: Chairman and Chief Executive Officer
  source text: an Executive Employment Agreement, effective as of February 14, 2025, with Paul L. Berns, as the Company’s Chairman and Chief Executive Officer
  evidence_url: https://www.sec.gov/Archives/edgar/data/1885522/000119312525031974/0001193125-25-031974-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.